MindBio Therapeutics (WF60) Stock Overview
Engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
WF60 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
MindBio Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.28 |
| 52 Week High | CA$8.80 |
| 52 Week Low | CA$0.16 |
| Beta | -0.37 |
| 1 Month Change | -68.58% |
| 3 Month Change | -76.96% |
| 1 Year Change | -90.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| WF60 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -56.5% | 6.4% | 1.6% |
| 1Y | -90.1% | 0.002% | 11.5% |
Return vs Industry: WF60 underperformed the German Pharmaceuticals industry which returned 0% over the past year.
Return vs Market: WF60 underperformed the German Market which returned 11.5% over the past year.
Price Volatility
| WF60 volatility | |
|---|---|
| WF60 Average Weekly Movement | 136.6% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: WF60's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: WF60's weekly volatility has decreased from 714% to 137% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Justin Hanka | www.mindbiotherapeutics.com |
MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain.
MindBio Therapeutics Corp. Fundamentals Summary
| WF60 fundamental statistics | |
|---|---|
| Market cap | €627.91k |
| Earnings (TTM) | -€2.23m |
| Revenue (TTM) | n/a |
Is WF60 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WF60 income statement (TTM) | |
|---|---|
| Revenue | AU$0 |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$0 |
| Other Expenses | AU$3.97m |
| Earnings | -AU$3.97m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.94 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -90.2% |
How did WF60 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/26 23:50 |
| End of Day Share Price | 2025/11/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MindBio Therapeutics Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.